STOCK TITAN
  1. Home
  2. News
  3. AZN

AstraZeneca PLC - AZN STOCK NEWS

Welcome to our dedicated page for AstraZeneca PLC news (Ticker: AZN), a resource for investors and traders seeking the latest updates and insights on AstraZeneca PLC stock.

AstraZeneca PLC (AZN) is a British-Swedish multinational pharmaceutical and biotechnology company headquartered in Cambridge, England. Formed in 1999 through the merger of Astra AB of Sweden and Zeneca Group PLC of the UK, AstraZeneca is known for its extensive research and development in the field of pharmaceuticals and biotechnology.

The company operates globally and generates a significant portion of its revenue from international markets, with the United States accounting for nearly one-third of its sales. AstraZeneca’s product portfolio includes a wide range of branded drugs across several major therapeutic areas such as gastrointestinal, diabetes, cardiovascular, respiratory, oncology, immunology, and rare diseases.

Recent achievements include a global license agreement with Nona Biosciences to develop preclinical monoclonal antibodies aimed at creating targeted therapies in oncology. The agreement could potentially bring Nona Biosciences up to $575 million upon achieving specified milestones, as well as tiered royalty payments on net sales. AstraZeneca continues to lead in the development of tumor-targeted therapies using cutting-edge technology.

Another noteworthy development is AstraZeneca's collaboration with AbelZeta Pharma to co-develop C-CAR031, a GPC3-targeted CAR-T therapy for treating hepatocellular carcinoma (HCC). The initial clinical results presented at the 2024 ASCO Annual Meeting showed promising safety and efficacy data.

Moreover, AstraZeneca has entered into a significant agreement with Compugen Ltd. to develop rilvegostomig, a PD-1/TIGIT bispecific antibody currently in Phase 3 trials for non-small cell lung cancer and biliary tract cancer. This partnership underscores AstraZeneca’s commitment to advancing innovative cancer therapies through strategic collaborations.

With its industry-leading capabilities, AstraZeneca is well-positioned to continue making significant strides in healthcare, providing effective treatments for a variety of diseases and maintaining its reputation as a global leader in pharmaceuticals and biotechnology.

News

Asher Bio Closes $55 Million Series C Financing to Advance Lead Program into Phase 1b Clinical Trials

Rhea-AI Summary
Asher Biotherapeutics closes $55 million Series C financing led by RA Capital Management to advance lead program AB248 into Phase 1b Clinical Trials with support from AstraZeneca and Bristol Myers Squibb.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
clinical trial
-
News

IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial

Rhea-AI Summary
AstraZeneca's IMFINZI in combination with chemotherapy doubled the overall survival rate at three years for patients with advanced biliary tract cancer in the TOPAZ-1 Phase III trial. The results showed a 26% reduction in the risk of death compared to chemotherapy alone, with a median OS of 12.9 months for the combination therapy. The trial met the primary endpoint of OS in October 2021, showing a 20% reduction in the risk of death. IMFINZI plus chemotherapy continued to be well-tolerated with no new safety signals observed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
clinical trial
-
News

FASENRA approved for treatment of children aged 6 to 11 with severe asthma

Rhea-AI Summary
AstraZeneca's FASENRA (benralizumab) receives FDA approval for pediatric patients aged 6 to 11 with severe eosinophilic asthma, expanding treatment options. The approval is based on TATE trial data and prior trials, with a recommended dose of 30 mg for patients 6 years and older.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.97%
Tags
none
News

ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors

Rhea-AI Summary
Daiichi Sankyo and AstraZeneca's ENHERTU receives U.S. FDA approval for the treatment of HER2 positive solid tumors after showing clinically meaningful responses. The drug is now approved for five indications, with the latest in metastatic cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.37%
Tags
none
-
News

ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors

Rhea-AI Summary
AstraZeneca and Daiichi Sankyo's ENHERTU gains accelerated approval in the US for HER2-positive solid tumors, marking a significant milestone in targeted cancer treatment. The approval is based on positive response rates and duration of response in Phase II trials, leading to inclusion in NCCN Guidelines®.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.37%
Tags
none
-
News

IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial

Rhea-AI Summary
AstraZeneca's IMFINZI shows survival benefit in Phase III trial for -stage small cell lung cancer, marking a breakthrough in treatment. Positive results in OS and PFS with no new safety signals identified. IMFINZI continues to lead in lung cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.16%
Tags
clinical trial
News

Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

Rhea-AI Summary
Daiichi Sankyo and AstraZeneca's Biologics License Application for datopotamab deruxtecan has been accepted in the U.S. for the treatment of advanced nonsquamous non-small cell lung cancer and HR positive, HER2 negative breast cancer. The BLA is based on positive results from the TROPION-Breast01 phase 3 trial, with a PDUFA date set for January 29, 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.37%
Tags
none
-
News

VOYDEYA™ approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular hemolysis in adults with the rare disease PNH

Rhea-AI Summary
VOYDEYA (danicopan) has been approved in the US as an add-on therapy for extravascular hemolysis in adults with paroxysmal nocturnal hemoglobinuria. The approval was based on positive results from the pivotal ALPHA Phase III trial, showing efficacy in addressing EVH. VOYDEYA met primary and secondary endpoints, was well-tolerated, and received Breakthrough Therapy designation and PRIME status.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
none
-
News

ULTOMIRIS® (ravulizumab-cwvz) approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD)

Rhea-AI Summary
ULTOMIRIS, the first long-acting C5 complement inhibitor, receives US FDA approval for treating AQP4 Ab+ NMOSD, showing a 98.6% relapse risk reduction in the CHAMPION-NMOSD trial. NMOSD is a rare autoimmune disease affecting the CNS, with about 6,000 diagnosed cases in the US. The safety profile of ULTOMIRIS remains consistent with previous studies, with COVID-19, headache, back pain, arthralgia, and urinary tract infection being the most common adverse events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.6%
Tags
none
News

AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer

Rhea-AI Summary
AstraZeneca acquires Fusion Pharmaceuticals Inc., a clinical-stage company developing radioconjugates for cancer treatment. The acquisition aims to enhance AstraZeneca's oncology portfolio with a focus on prostate cancer treatment. The deal includes a transaction value of approximately $2.4bn, bringing new expertise and capabilities to AstraZeneca.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.02%
Tags
acquisition

FAQ

What is the current stock price of AstraZeneca PLC (AZN)?

The current stock price of AstraZeneca PLC (AZN) is $66.26 as of December 27, 2024.

What is the market cap of AstraZeneca PLC (AZN)?

The market cap of AstraZeneca PLC (AZN) is approximately 206.3B.

What is AstraZeneca PLC?

AstraZeneca PLC is a British-Swedish multinational pharmaceutical and biotechnology company formed in 1999 through the merger of Astra AB of Sweden and Zeneca Group PLC of the UK. It is headquartered in Cambridge, England.

What therapeutic areas does AstraZeneca focus on?

AstraZeneca’s product portfolio includes drugs across several therapeutic areas such as gastrointestinal, diabetes, cardiovascular, respiratory, oncology, immunology, and rare diseases.

Where does AstraZeneca generate most of its revenue?

A significant portion of AstraZeneca’s revenue comes from international markets, with the United States accounting for nearly one-third of its sales.

What is the recent collaboration between AstraZeneca and Nona Biosciences about?

AstraZeneca and Nona Biosciences have entered into a global license agreement to develop preclinical monoclonal antibodies aimed at creating targeted therapies in oncology.

What is C-CAR031?

C-CAR031 is a GPC3-targeted CAR-T therapy developed by AstraZeneca and AbelZeta Pharma for treating hepatocellular carcinoma (HCC). Initial clinical results have shown promising safety and efficacy data.

What is rilvegostomig?

Rilvegostomig is a PD-1/TIGIT bispecific antibody developed by AstraZeneca in collaboration with Compugen Ltd. It is currently in Phase 3 trials for non-small cell lung cancer and biliary tract cancer.

What are some of AstraZeneca’s key recent achievements?

Recent achievements include a global license agreement with Nona Biosciences for oncology therapies, collaboration with AbelZeta Pharma on C-CAR031, and partnership with Compugen Ltd. for developing rilvegostomig.

Where is AstraZeneca headquartered?

AstraZeneca is headquartered at the Cambridge Biomedical Campus in Cambridge, England.

When was AstraZeneca formed?

AstraZeneca was formed in 1999 through the merger of Astra AB of Sweden and Zeneca Group PLC of the UK.

What is the focus of AstraZeneca’s research and development?

AstraZeneca focuses on research and development in pharmaceuticals and biotechnology, particularly in creating treatments for various major therapeutic areas including cancer, respiratory diseases, cardiovascular conditions, and more.

Stock AZN logo
AstraZeneca PLC

Nasdaq:AZN

AZN Rankings

#45 Ranked by Market Cap
#1585 Ranked by Dividends

AZN Stock Data

206.25B
3.10B
0.01%
16.76%
0.24%
Drug Manufacturers - General
Healthcare
Link
United States of America
Cambridge